fda warning bpc-157 peptide unapproved letter new drug BPC-157: Miracle Healing or Hidden Danger? Understanding the Legal Risks of
Description
[5] Topical GHK-Cu is generally considered well tolerated, yet therapy should be avoided in individuals with a known hypersensitivity to copper peptides or any vehicle component
In vitro analytical peptide research
10.1038/nrc3239 136 PastonS
However, the trial is listed as canceled, which indicates the study sponsor or investigator recalled a submission of study results before quality control review took place
